参考文献
关键文献
Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141 (2 Suppl):e227S-77S.全文 摘要
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e278S-325S.全文 摘要
Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141 (2 Suppl):e195S-226S.全文 摘要
National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Aug 2019 [internet publication].全文
Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism - international consensus statement. Int Angiol. 2013 Apr;32(2):111-260.全文 摘要
参考文献
1. Huisman MV, Büller HR, ten Cate JW, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest. 1989 Mar;95(3):498-502. 摘要
2. Shojania KG, Duncan BW, McDonald KM, et al. Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ). 2001;(43):i-x;1-668.全文 摘要
3. Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141 (2 Suppl):e227S-77S.全文 摘要
4. Zhan C, Miller MR. Excess length of stay, charges, and mortality attributable to medical injuries during hospitalization. JAMA. 2003 Oct 8;290(14):1868-74.全文 摘要
5. Becattini C, Agnelli G, Pesavento R, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest. 2006 Jul;130(1):172-5. 摘要
6. Pengo V, Lensing AW, Prins MH, et al; Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 May 27;350(22):2257-64.全文 摘要
7. Kahn SR, Ginsberg JS. The post-thrombotic syndrome: current knowledge, controversies, and directions for future research. Blood Rev. 2002 Sep;16(3):155-65. 摘要
8. Cervantes J, Rojas G. Virchow's legacy: deep vein thrombosis and pulmonary embolism. World J Surg. 2005;29 Suppl 1:S30-4. 摘要
9. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ. 1992 Sep 5;305(6853):567-74.全文 摘要
10. Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002 Oct 19;325(7369):887-90.全文 摘要
11. Cogo A, Lensing AW, Prandoni P, et al. Distribution of thrombosis in patients with symptomatic deep vein thrombosis: implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med. 1993 Dec 27;153(24):2777-80. 摘要
12. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974 Jul;27(7):517-28.全文 摘要
13. McIntyre KM, Sasahara AA. The hemodynamic response to pulmonary embolism in patients without prior cardiopulmonary disease. Am J Cardiol. 1971 Sep;28(3):288-94. 摘要
14. Samama MM. Epidemiology of risk factors of deep venous thrombosis (DVT) of the lower limbs in community practice: the SIRIUS study. Abstract: XIVth Congress of the International Society on Thrombosis and Haemostasis. New York, New York, USA. July 4-9, 1993. Thromb Haemost. 1993 Jun 30;69(6):763. 摘要
15. Bonifacj C, Quere I, Dupuy C, et al. Case control studies of the risk factors for deep-vein thrombosis in an adult population hospitalized in internal medicine [in French]. Rev Epidemiol Sante Publique. 1997 Dec;45(6):465-73. 摘要
16. Samama MM, Dahl OE, Quinlan DJ, et al. Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica. 2003 Dec;88(12):1410-21.全文 摘要
17. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002 May 27;162(10):1182-9.全文 摘要
18. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000 May 2;132(9):689-96. 摘要
19. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002 Jun;87(6):1076-7. 摘要
20. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest. 2009;27 Suppl 1:63-74. 摘要
21. Otten HM, Mathijssen J, ten Cate H, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med. 2004 Jan 26;164(2):190-4.全文 摘要
22. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118(5):555-68. 摘要
23. Heit JA. Venous thromboembolism epidemiology: implications for prevention and management. Semin Thromb Hemost. 2002 Jun;28 Suppl 2:3-13. 摘要
24. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23. 摘要
25. Joynt GM, Kew J, Gomersall CD, et al. Deep venous thrombosis caused by femoral venous catheters in critically ill adult patients. Chest. 2000 Jan;117(1):178-83. 摘要
26. Wehmeier A, Daum I, Jamin H, et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders: a retrospective analysis of 260 patients. Ann Hematol. 1991 Aug;63(2):101-6. 摘要
27. Leone G, Sica S, Chiusolo P, et al. Blood cell diseases and thrombosis. Haematologica. 2001 Dec;86(12):1236-44.全文 摘要
28. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15.全文 摘要
29. Bernstein CN, Blanchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001 Mar;85(3):430-4. 摘要
30. Anderson FA Jr., Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med. 1991 May;151(5):933-8. 摘要
31. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997 Feb 26;277(8):642-5. 摘要
32. Douketis JD, Ginsberg JS, Holbrook A, et al. A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med. 1997 Jul 28;157(14):1522-30. 摘要
33. Suissa S, Blais L, Spitzer WO, et al. First-time use of newer oral contraceptives and the risk of venous thromboembolism. Contraception. 1997 Sep;56(3):141-6. 摘要
34. Goodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996 Oct 12;348(9033):983-7. 摘要
35. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999 Aug;82(2):610-9. 摘要
36. Klil-Drori AJ, Yin H, Tagalakis V, et al. Androgen deprivation therapy for prostate cancer and the risk of venous thromboembolism. Eur Urol. 2016 Jul;70(1):56-61. 摘要
37. Oger E, Leroyer C, Le Moigne E, et al. The value of a risk factor analysis in clinically suspected deep venous thrombosis. Respiration. 1997;64(5):326-30. 摘要
38. Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism: the Framingham Study. Am J Med. 1983 Jun;74(6):1023-8. 摘要
39. Atrash HK, Koonin LM, Lawson HW, et al. Maternal morbidity in the United States 1979-1986. Obstet Gynecol. 1990 Dec;76(6):1055-60. 摘要
40. Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand. 1983;62(3):239-43. 摘要
41. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000 Dec 11-25;160(22):3415-20.全文 摘要
42. Philbrick JT, Shumate R, Siadaty MS, et al. Air travel and venous thromboembolism: a systematic review. J Gen Intern Med. 2007 Jan;22(1):107-14.全文 摘要
43. Lapostolle FK, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001 Sep 13;345(11):779-83.全文 摘要
44. ten Wolde M, Kraaijenhagen RA, Schiereck J, et al. Travel and the risk of symptomatic venous thromboembolism. Thromb Haemost. 2003 Mar;89(3):499-505. 摘要
45. Zee AA, van Lieshout K, van der Heide M, et al. Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-limb immobilization. Cochrane Database Syst Rev. 2017 Aug 6;(8):CD006681.全文 摘要
46. van Adrichem RA, Nemeth B, Algra A, et al; POT-KAST and POT-CAST Group. Thromboprophylaxis after knee arthroscopy and lower-leg casting. N Engl J Med. 2017 Feb 9;376(6):515-25.全文 摘要
47. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e278S-325S.全文 摘要
48. Zöller B, Ohlsson H, Sundquist J, et al. Family history of venous thromboembolism (VTE) and risk of recurrent hospitalization for VTE: a nationwide family study in Sweden. J Thromb Haemost. 2014;12(3):306-12.全文 摘要
49. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141 (2 Suppl):e195S-226S.全文 摘要
50. National Institute for Health and Care Excellence. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Aug 2019 [internet publication].全文
51. Hostler DC, Marx ES, Moores LK, et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk score. Chest. 2016 Feb;149(2):372-9. 摘要
52. Rosenberg DJ, Press A, Fishbein J, et al. External validation of the IMPROVE bleeding risk assessment model in medical patients. Thromb Haemost. 2016 Aug 30;116(3):530-6. 摘要
53. Horlocker TT, Vandermeuelen E, Kopp SL, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). Reg Anesth Pain Med. 2018 Apr;43(3):263-309. 摘要
54. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001 Apr 26;344(17):1286-92.全文 摘要
55. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf. 2003;26(3):197-207. 摘要
56. Lim W, Dentali F, Eikelboom JW, et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006 May 2;144(9):673-84. 摘要
57. Samama MM, Cohen AT, Darmon JY, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999 Sep 9;341(11):793-800.全文 摘要
58. Falanga A, Ay C, Di Nisio M, et al. Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. 2023 Jan 10;1016.全文 摘要
59. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer-associated venous thromboembolic disease [internet publication].全文
60. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020 Feb 10;38(5):496-520.全文 摘要
61. Farge D, Frere C, Connors JM, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022 Jul;23(7):e334-47.全文 摘要
62. Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019 Feb 21;380(8):711-9.全文 摘要
63. Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019 Feb 21;380(8):720-8.全文 摘要
64. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism - international consensus statement. Int Angiol. 2013 Apr;32(2):111-260.全文 摘要
65. Liu N, Vigod SN, Farrugia MM, et al. Venous thromboembolism after induced abortion: a population-based, propensity-score-matched cohort study in Canada. Lancet Haematol. 2018 Jul;5(7):e279-88. 摘要
66. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv. 2019 Dec 10;3(23):3898-944.全文 摘要
67. Dahl OE, Caprini JA, Colwell CW Jr, et al. Fatal vascular outcomes following major orthopedic surgery. Thromb Haemost. 2005 May;93(5):860-6. 摘要
68. Cordell-Smith JA, Williams SC, Harper WM, et al. Lower limb arthroplasty complicated by deep venous thrombosis: prevalence and subjective outcome. J Bone Joint Surg Br. 2004 Jan;86(1):99-101. 摘要
69. Sun Y, Chen D, Xu Z, et al. Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. Arthroscopy. 2014 Mar;30(3):406-12. 摘要
70. Perrotta C, Chahla J, Badariotti G, et al. Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. Cochrane Database Syst Rev. 2020 May 6;(5):CD005259.全文 摘要
71. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008 Feb 2;371(9610):387-94. [Erratum in: Lancet. 2008 Jun 7;371(9628):1914.] 摘要
72. Kucher N, Spirk D, Kalka C, et al. Clinical predictors of prophylaxis use prior to the onset of acute venous thromboembolism in hospitalized patients SWIss Venous ThromboEmbolism Registry (SWIVTER). J Thromb Haemost. 2008 Dec;6(12):2082-7. 摘要
73. Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005 Mar;241(3):397-415.全文 摘要
74. Mosen D, Elliott CG, Egger MJ, et al. The effect of a computerized reminder system on the prevention of postoperative venous thromboembolism. Chest. 2004 May;125(5):1635-41. 摘要
75. Abdel-Razeq H. Venous thromboembolism prophylaxis for hospitalized medical patients, current status and strategies to improve. Ann Thorac Med. 2010 Oct;5(4):195-200. 摘要
76. Canadian Patient Safety Institute. Safer healthcare now! 2016 [internet publication].全文
77. Mahan CE, Spyropoulos AC. Venous thromboembolism prevention: a systematic review of methods to improve prophylaxis and decrease events in the hospitalized patient. Hosp Pract (1995). 2010 Feb;38(1):97-108. 摘要
78. Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013 Jun 4;158(11):800-6. 摘要
79. National Institute for Health and Care Excellence. Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults. Apr 2009 [internet publication].全文
80. Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv. 2018 Nov 27;2(22):3198-225.全文 摘要
81. National Institute for Health and Care Excellence. Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. Sep 2008 [internet publication].全文
82. National Institute for Health and Care Excellence. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. Jan 2012 [internet publication].全文
83. Eikelboom JW, Connolly SJ, Brueckmann M, et al; the RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. 摘要
84. Cohen AT, Spiro TE, Büller HR, et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23.全文 摘要
85. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; ADOPT Trial Investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011 Dec 8;365(23):2167-77.全文 摘要
86. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018 Sep 20;379(12):1118-27.全文 摘要
87. Sachdeva A, Dalton M, Lees T. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev. 2018 Nov 3;(11):CD001484.全文 摘要
88. Dennis M, Sandercock PA, Reid J, et al; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009 Jun 6;373(9679):1958-65.全文 摘要
89. Pour AE, Keshavarzi NR, Purtill JJ, et al. Is venous foot pump effective in prevention of thromboembolic disease after joint arthroplasty: a meta-analysis. J Arthroplasty. 2013 Mar;28(3):410-7. 摘要
90. Hardwick ME, Pulido PA, Colwell CW Jr. A mobile compression device compared with low-molecular-weight heparin for prevention of venous thromboembolism in total hip arthroplasty. Orthop Nurs. 2011 Sep-Oct;30(5):312-6. 摘要
91. Dennis M, Caso V, Kappelle LJ, et al. European Stroke Organization guidelines for prophylaxis for venous thromboembolism in immobile patients with acute ischaemic stroke. Eur Stroke J. 2016 Mar;1(1):6-19.全文
92. Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-14. 摘要
93. Lederle FA, Zylla D, MacDonald R, et al. Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2011 Nov 1;155(9):602-15. 摘要
94. Dentali F, Mumoli N, Prisco D, et al. Efficacy and safety of extended thromboprophylaxis for medically ill patients. A meta-analysis of randomised controlled trials. Thromb Haemost. 2017 Feb 28;117(3):606-17. 摘要
95. Bajaj NS, Vaduganathan M, Qamar A, et al. Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. PLoS Med. 2019 Apr;16(4):e1002797.全文 摘要
96. Chi G, Sharfaei S, Jafarizade M, et al. Extended or shorter prophylaxis for venous thromboembolism in acutely ill hospitalized patients: updated meta-analysis of randomized trials. Vasc Med. 2019 Apr;24(2):156-8.全文 摘要
97. Bhalla V, Lamping OF, Abdel-Latif A, et al. Contemporary meta-analysis of extended direct-acting oral anticoagulant thromboprophylaxis to prevent venous thromboembolism. Am J Med. 2020 Sep;133(9):1074-81.全文 摘要
98. Hull RD, Schellong SM, Tapson VF, et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. 摘要
99. Sharma A, Chatterjee S, Lichstein E, et al. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012 Oct;10(10):2053-60. 摘要
100. Cook D, Meade M, Guyatt G, et al; PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011 Apr 7;364(14):1305-14.全文 摘要
101. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021 Feb 23;5(4):927-74.全文 摘要
102. Rutjes AW, Porreca E, Candeloro M, et al. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev. 2020 Dec 18;(12):CD008500.全文 摘要
103. Kahale LA, Matar CF, Tsolakian I, et al. Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev. 2021 Oct 8;(10):CD006466.全文 摘要
104. Barbarawi M, Zayed Y, Kheiri B, et al. The role of anticoagulation in venous thromboembolism primary prophylaxis in patients with malignancy: a systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2019 Sep;181:36-45.全文 摘要
105. Chen H, Tao R, Zhao H, et al. Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Jan;99(5):e19000.全文 摘要
106. Li A, Kuderer NM, Garcia DA, et al. Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis. J Thromb Haemost. 2019 Dec;17(12):2141-51.全文 摘要
107. Kahale LA, Tsolakian IG, Hakoum MB, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2018 Jun 1;(6):CD006468.全文 摘要
108. Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019 Nov;94(11):1176-84.全文 摘要
109. Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019 Jul 1;17(7):840-7.全文 摘要
110. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Multiple myeloma [internet publication].全文
111. Al-Ani F, Bermejo JM, Mateos MV, et al. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - a systematic review. Thromb Res. 2016 May;141:84-90. 摘要
112. Kahale LA, Matar CF, Tsolakian I, et al. Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD014739.全文 摘要
113. Shalhoub J, Lawton R, Hudson J, et al. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ. 2020 May 13;369:m1309.全文 摘要
114. Felder S, Rasmussen MS, King R, et al. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. Cochrane Database Syst Rev. 2019 Aug 26;(8):CD004318.全文 摘要
115. Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007 Sep 15;370(9591):949-56. 摘要
116. Eriksson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007 Nov;5(11):2178-85.全文 摘要
117. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*): a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011 Apr;105(4):721-9. 摘要
118. Ginsberg JS, Davidson BL, Comp PC, et al; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan;24(1):1-9. 摘要
119. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009 May 16;373(9676):1673-80. 摘要
120. Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008 Jul 5;372(9632):31-9. 摘要
121. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2765-75.全文 摘要
122. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008 Jun 26;358(26):2776-86.全文 摘要
123. Lassen MR, Raskob GE, Gallus A, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 6;375(9717):807-15. 摘要
124. Lassen MR, Gallus A, Raskob GE, et al; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. 摘要
125. Anderson DR, Dunbar M, Murnaghan J, et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med. 2018 Feb 22;378(8):699-707. 摘要
126. CRISTAL Study Group, Sidhu VS, Kelly TL, et al. Effect of Aspirin vs Enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee arthroplasty: The CRISTAL Randomized Trial. JAMA. 2022 Aug 23;328(8):719-27.全文 摘要
127. Forster R, Stewart M. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair. Cochrane Database Syst Rev. 2016 Mar 30;(3):CD004179.全文 摘要
128. Major Extremity Trauma Research Consortium (METRC), O'Toole RV, Stein DM, et al. Aspirin or low-molecular-weight heparin for thromboprophylaxis after a fracture. N Engl J Med. 2023 Jan 19;388(3):203-13. 摘要
129. Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or enoxaparin in nonmajor orthopedic surgery. N Engl J Med. 2020 May 14;382(20):1916-25.全文 摘要
130. Amaral FC, Baptista-Silva JC, Nakano LC, et al. Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. Cochrane Database Syst Rev. 2022 Nov 22;11(11):CD013683.全文 摘要
131. Mahé I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost. 2007 Apr;97(4):581-6. 摘要
132. Douketis J, Cook D, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med. 2008 Sep 8;168(16):1805-12.全文 摘要
133. Schmid P, Brodmann D, Fischer AG, et al. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8.全文 摘要
134. Rondina MT, Wheeler M, Rodgers GM, et al. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-Ill patients. Thromb Res. 2010 Mar;125(3):220-3.全文 摘要
135. Ceccato D, Di Vincenzo A, Pagano C, et al. Weight-adjusted versus fixed dose heparin thromboprophylaxis in hospitalized obese patients: a systematic review and meta-analysis. Eur J Intern Med. 2021 Jun;88:73-80.全文 摘要
136. Mahmoodi BK, Cushman M, Anne Næss I, et al. Association of traditional cardiovascular risk factors with venous thromboembolism: an individual participant data meta-analysis of prospective studies. Circulation. 2017 Jan 3;135(1):7-16. [Erratum in: Circulation. 2017 Mar 21;135(12):e788.]全文 摘要
137. Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 suppl):e691S-e736S.全文 摘要
138. Zareba P, Wu C, Agzarian J, et al. Meta-analysis of randomized trials comparing combined compression and anticoagulation with either modality alone for prevention of venous thromboembolism after surgery. Br J Surg. 2014 Aug;101(9):1053-62. 摘要
139. Kakkos S, Kirkilesis G, Caprini JA, et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev. 2022 Jan 28;(1):CD005258.全文 摘要
140. Salazar CA, Malaga G, Malasquez G. Direct thrombin inhibitors versus vitamin K antagonists or low molecular weight heparins for prevention of venous thromboembolism following total hip or knee replacement. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD005981.全文 摘要
141. Melillo SN, Scanlon JV, Exter BP, et al. Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. 摘要
142. Lalonde L, Martineau J, Blais N, et al. Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J. 2008 Jul;156(1):148-54. 摘要
143. Hull RD, Yusen RD, Bergqvist D. State-of-the-art review: assessing the safety profiles of new anticoagulants for major orthopedic surgery thromboprophylaxis. Clin Appl Thromb Hemost. 2009 Jul-Aug;15(4):377-88. 摘要
144. Selby R, Geerts WH, Kreder HJ, et al; D-KAF (Dalteparin in Knee-to-Ankle Fracture) Investigators. A double-blind, randomized controlled trial of the prevention of clinically important venous thromboembolism after isolated lower leg fractures. J Orthop Trauma. 2015 May;29(5):224-30. 摘要
145. Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. N Engl J Med. 2021 Aug 12;385(7):609-17.全文 摘要
146. Weitz JI, Strony J, Ageno W, et al. Milvexian for the prevention of venous thromboembolism. N Engl J Med. 2021 Dec 2;385(23):2161-72.全文 摘要
147. Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: The FOXTROT Randomized Clinical Trial. JAMA. 2020 Jan 14;323(2):130-9.全文 摘要
148. Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med. 2004 Jul 15;351(3):268-77. 摘要
149. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306.全文 摘要
150. Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Aug 4;76(5):594-622.全文 摘要
151. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015 Aug 6;373(6):511-20.全文 摘要
152. Khan F, Rahman A, Carrier M, et al. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis. BMJ. 2019 Jul 24;366:l4363.全文 摘要
153. Becattini C, Agnelli G, Schenone A, et al; WARFASA Investigators. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med. 2012 May 24;366(21):1959-67.全文 摘要
154. Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic therapy for VTE disease: Second update of the CHEST guideline and expert panel report. Chest. 2021 Dec;160(6):e545-608.全文 摘要
155. Weitz JI, Lensing AW, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017 Mar 30;376(13):1211-22.全文 摘要
156. Büller HR, Décousus H, Grosso MA, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15.全文 摘要
157. Raskob GE, van Es N, Verhamme P, et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018 Feb 15;378(7):615-24. 摘要
内容使用需遵循免责声明